Read by QxMD icon Read


Armando Santoro, Rita Mazza, Alessandro Pulsoni, Alessandro Re, Maurizio Bonfichi, Vittorio Ruggero Zilioli, Flavia Salvi, Francesco Merli, Antonella Anastasia, Stefano Luminari, Giorgia Annechini, Manuel Gotti, Annalisa Peli, Anna Marina Liberati, Nicola Di Renzo, Luca Castagna, Laura Giordano, Carmelo Carlo-Stella
PURPOSE: This multicenter, open-label, phase II study evaluated the combination of bendamustine, gemcitabine, and vinorelbine (BeGEV) as induction therapy before autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory Hodgkin lymphoma (HL). PATIENTS AND METHODS: Patients with HL who were refractory to or had relapsed after one previous chemotherapy line were eligible. The primary end point was complete response (CR) rate after four cycles of therapy...
September 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Manuel Gotti, Marta Nicola, Marco Lucioni, Valeria Fiaccadori, Virginia Ferretti, Roberta Sciarra, Mariangela Costanza, Elisa Bono, Silvana Molo, Aldo Maffi, Giorgio A Croci, Marzia Varettoni, Marco Frigeni, Cristiana Pascutto, Luca Arcaini, Maurizio Bonfichi, Marco Paulli, Mario Cazzola
Although patients with early-stage Hodgkin's lymphoma have a high rate of cure, a portion of these are resistant to or relapse after standard treatment. Current prognostic criteria based on clinical and laboratory parameters at diagnosis do not allow to accurately identify the subset of patients with less favourable clinical outcome. An increased number of tumour-infiltrating macrophages was found to be associated with shortened survival in patients with classic Hodgkin's Lymphoma. The aim of this study was to assess the clinical significance of the proportion of CD68-positive infiltrating macrophages in patients with early-stage classic Hodgkin's lymphoma...
April 6, 2016: Hematological Oncology
Pier Luigi Zinzani, Alessandro Broccoli, Daniela Maria Gioia, Antonio Castagnoli, Giovannino Ciccone, Andrea Evangelista, Armando Santoro, Umberto Ricardi, Maurizio Bonfichi, Ercole Brusamolino, Giuseppe Rossi, Antonella Anastasia, Francesco Zaja, Umberto Vitolo, Vincenzo Pavone, Alessandro Pulsoni, Luigi Rigacci, Gianluca Gaidano, Caterina Stelitano, Flavia Salvi, Chiara Rusconi, Monica Tani, Roberto Freilone, Patrizia Pregno, Eugenio Borsatti, Gian Mauro Sacchetti, Lisa Argnani, Alessandro Levis
PURPOSE: The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a rationale to shift patients who respond poorly onto a more intensive regimen (PET response-adapted therapy), remains to be confirmed. PATIENTS AND METHODS: The phase II part of the multicenter HD0801 study involved 519 patients with advanced-stage de novo Hodgkin lymphoma who received an initial treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and who underwent an early ifosfamide-containing salvage treatment followed by stem-cell transplantation if they showed a positive PET evaluation after two cycles of chemotherapy (PET2)...
April 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Monica Balzarotti, Ercole Brusamolino, Emanuele Angelucci, Angelo Michele Carella, Umberto Vitolo, Eleonora Russo, Angelagiovanna Congiu, Manuel Gotti, Stefania Massidda, Barbara Botto, Giorgia Annechini, Michele Spina, Alessandro Re, Vittorio Ruggero Zilioli, Francesco Merli, Flavia Salvi, Caterina Stelitano, Maurizio Bonfichi, Marcello Rodari, Roberta Murru, Massimo Magagnoli, Antonella Anastasia, Rita Mazza, Laura Giordano, Armando Santoro
This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m(2)) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The primary endpoint was the complete response (CR) proportion, evaluated by FDG-PET, after induction chemotherapy. CR proportion was 39% with B-IGEV and 53% with IGEV. PFS and OS were similar between the two groups (two-year PFS: 58% vs 56%; two-year OS: 93% vs 81%)...
October 2016: Leukemia & Lymphoma
Lorenzo Magrassi, Elena Moretti, Marco Marchionni, Elisa Rognone, Bonfichi Maurizio
BACKGROUND: Biopsies of clival lesions are usually performed, under general anaesthesia, through an anterior endoscopic approach or, alternatively, through a trans-nasal or trans-oral stereotactic approach. METHODS: A 57-year-old man with a symptomatic osteolytical lesion of the clivus, who refused general anaesthesia, underwent a sterotactically guided biopsy of the lesion by an antero-lateral approach through the temporal and sphenoid bones. RESULTS: Biopsy was successfully performed and the resulting diagnosis was myeloma...
April 2016: Acta Neurochirurgica
Luca Arcaini, Lucia Morello, Alessandra Tucci, Chiara Rusconi, Marco Ladetto, Sara Rattotti, Maurizio Bonfichi, Chiara Bottelli, Cristina Gabutti, Paolo Bernasconi, Marzia Varettoni, Manuel Gotti, Daniela Troletti, Maria Luisa Guerrera, Valeria Fiaccadori, Roberta Sciarra, Virginia Valeria Ferretti, Emilio Paolo Alessandrino, Giuseppe Rossi, Enrica Morra
High-dose chemotherapy with autologous stem cell transplantation (ASCT) has been shown effective in the control of relapsed/refractory follicular lymphoma. We evaluate the long-term outcome of patients with relapsed or refractory follicular lymphoma treated with ASCT with in vivo purged progenitors cells. We report the long-term results of a prospective multicenter phase 2 trial on 124 relapsed/refractory follicular lymphoma patients treated with a program of anthracycline-based debulking chemotherapy, immunochemotherapy, mobilization of in vivo purged PBSC followed by ASCT...
March 2015: American Journal of Hematology
Luca Arcaini, Davide Rossi, Marco Lucioni, Marta Nicola, Alessio Bruscaggin, Valeria Fiaccadori, Roberta Riboni, Antonio Ramponi, Virginia V Ferretti, Stefania Cresta, Gloria Margiotta Casaluci, Maurizio Bonfichi, Manuel Gotti, Michele Merli, Aldo Maffi, Mariarosa Arra, Marzia Varettoni, Sara Rattotti, Lucia Morello, Maria Luisa Guerrera, Roberta Sciarra, Gianluca Gaidano, Mario Cazzola, Marco Paulli
Hepatitis C virus has been found to be associated with B-cell non-Hodgkin lymphomas, mostly marginal zone lymphomas and diffuse large B-cell lymphoma. Deregulation of signaling pathways involved in normal marginal zone development (NOTCH pathway, NF-κB, and BCR signaling) has been demonstrated in splenic marginal zone lymphoma. We studied mutations of NOTCH pathway signaling in 46 patients with hepatitis C virus-positive diffuse large B-cell lymphoma and in 64 patients with diffuse large B-cell lymphoma unrelated to HCV...
February 2015: Haematologica
Michele Merli, Carlo Visco, Michele Spina, Stefano Luminari, Virginia Valeria Ferretti, Manuel Gotti, Sara Rattotti, Valeria Fiaccadori, Chiara Rusconi, Clara Targhetta, Caterina Stelitano, Alessandro Levis, Achille Ambrosetti, Davide Rossi, Luigi Rigacci, Alfonso Maria D'Arco, Pellegrino Musto, Annalisa Chiappella, Luca Baldini, Maurizio Bonfichi, Luca Arcaini
A specific prognostication score for hepatitis C virus-positive diffuse large B-cell lymphomas is not available. For this purpose, the Fondazione Italiana Linfomi (FIL, Italian Lymphoma Foundation) carried out a multicenter retrospective study on a large consecutive series of patients with hepatitis C virus-associated diffuse large B-cell lymphoma to evaluate the prognostic impact of clinical and virological features and to develop a specific prognostic score for this subset of patients. All prognostic evaluations were performed on 535 patients treated with an anthracycline-based induction regimen (with rituximab in 255 cases)...
March 2014: Haematologica
Marzia Varettoni, Luca Arcaini, Silvia Zibellini, Emanuela Boveri, Sara Rattotti, Roberta Riboni, Alessandro Corso, Ester Orlandi, Maurizio Bonfichi, Manuel Gotti, Cristiana Pascutto, Silvia Mangiacavalli, Giorgio Croci, Valeria Fiaccadori, Lucia Morello, Maria Luisa Guerrera, Marco Paulli, Mario Cazzola
A study has shown that MYD88 (L265P) is a recurring somatic mutation in Waldenström's macroglobulinemia (WM). We developed an allele-specific polymerase chain reaction (PCR) for this mutation, and analyzed bone marrow or peripheral blood samples from 58 patients with WM, 77 with IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), 84 with splenic marginal zone lymphoma (SMZL), and 52 with B-cell chronic lymphoproliferative disorders (B-CLPD). MYD88 (L265P) was detected in 58/58 (100%) patients with WM, 36/77 (47%) with IgM-MGUS, 5/84 (6%) with SMZL, and 3/52 (4%) with B-CLPD...
March 28, 2013: Blood
Francesco Zaja, Stefano De Luca, Umberto Vitolo, Lorella Orsucci, Alessandro Levis, Flavia Salvi, Chiara Rusconi, Erika Ravelli, Alessandra Tucci, Chiara Bottelli, Monica Balzarotti, Ercole Brusamolino, Maurizio Bonfichi, Stefano A Pileri, Elena Sabattini, Stefano Volpetti, Chiara Monagheddu, Angelo Vacca, Roberto Ria, Renato Fanin
BACKGROUND: Preclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone. DESIGN AND METHODS: In this prospective, multicenter, phase II study, patients with relapsed/refractory mantle cell lymphoma who were not eligible for, or had relapsed after, intensive treatments received lenalidomide 25 mg/day (days 1-21 of each 28-day cycle) and dexamethasone (40 mg/day on days 1, 8, 15, and 22) for up to 12 months...
March 2012: Haematologica
Luca Arcaini, Daniele Laszlo, Silvia Rizzi, Monica Balzarotti, Francesca Antoniazzi, Vittorio Ruggero Zilioli, Elena Guggiari, Lucia Farina, Elisabetta Todisco, Maurizio Bonfichi, Sara Miqueleiz Alamos, Giuseppe Rossi, Giovanni Martinelli, Enrica Morra
Plerixafor has been previously reported to improve PBSC collection in pts undergoing PBSC mobilization. Aim of the study was to assess the efficacy of plerixafor and G-CSF in pts with lymphoma who failed previous attempts of PBSC mobilization with conventional schemes of chemotherapy+G-CSF. 35 heavily pre-treated lymphoma pts (29 NHL, 6 HL) classified as "poor mobilizers" were enrolled in a program of compassionate use of plerixafor in 7 Italian centres of REL (Rete Ematologica Lombarda). Median number of previous lines of therapy was 3 and median number of previous attempts of mobilizations was 2...
June 2011: Leukemia Research
Ercole Brusamolino, Margherita Maffioli, Maurizio Bonfichi, Umberto Vitolo
The field of treatment of diffuse large B-cell lymphoma has been in a continuous flux over the last 10-15 years owing to the introduction of new therapeutic approaches such as dose-dense chemotherapy, monoclonal antibodies and high-dose chemotherapy followed by autologous peripheral blood stem cell transplant. The use of clinical prognostic factors has improved our ability to predict the outcome of these lymphomas; moreover, the gene and protein expression pattern has been shown, at least in the pre-rituximab era, to be an independent and powerful prognostic indicator...
April 2008: Future Oncology
L Arcaini, F Montanari, E P Alessandrino, A Tucci, E Brusamolino, L Gargantini, R Cairoli, P Bernasconi, F Passamonti, M Bonfichi, V Zoli, C Bottelli, S Calatroni, D Troletti, M Merli, C Pascutto, I Majolino, G Rossi, E Morra, M Lazzarino
BACKGROUND: To evaluate the clinical outcome of patients with relapsed or refractory follicular lymphoma treated with immunochemotherapy, in vivo purging and high-dose therapy with autotransplant. PATIENTS AND METHODS: Sixty-four patients were enrolled in the trial. Primary end point was progression-free survival (PFS). Secondary end points were the in vivo purging effect on stem-cell harvest and the impact of molecular response on the outcome. RESULTS: At enrollment, 59% of patients were PCR+ for bcl-2 rearrangement in bone marrow (PCR-informative)...
July 2008: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Patrizia Zappasodi, Anna Maria Nosari, Cesare Astori, Dennis Ciapanna, Maurizio Bonfichi, Marzia Varettoni, Silvia Mangiacavalli, Enrica Morra, Mario Lazzarino, Alessandro Corso
BACKGROUND: Pegylated filgrastim (PEG-f), a long-lasting granulocyte-colony-stimulating factor, has been used in different hematologic conditions to shorten chemotherapy-induced neutropenia and to mobilize peripheral blood stem cells. Data on mobilization efficacy in patients with multiple myeloma are, however, still limited. STUDY DESIGN AND METHODS: The feasibility and mobilizing capacity of DCEP chemotherapy followed by a single subcutaneous dose of 6 mg of PEG-f in 23 myeloma patients (11 females and 12 males) whose median age was 55 years (range, 31-67 years) were investigated...
May 2008: Transfusion
Alfredo La Fianza, Maurizio Bonfichi, Maria Sole Prevedoni Gorone, Anna Gallotti, Lorella Torretta
The standard therapy for patients affected by acute promyelocytic leukemia is based on all-trans-retinoic acid (ATRA), whose rare complication is a syndrome known as retinoic acid syndrome. We describe for the first time the computed tomography findings of a case of ATRA syndrome with typical pulmonary findings, along with the involvement of the upper abdomen organs (liver and spleen) as a further complication of the pathology.
July 2007: Clinical Imaging
Luciano Bernardi, Claudio Passino, Giammario Spadacini, Maurizio Bonfichi, Luca Arcaini, Luca Malcovati, Gabriele Bandinelli, Annette Schneider, Cornelius Keyl, Paul Feil, Richard E Greene, Carlo Bernasconi
Yoga induces long-term changes in respiratory function and control. We tested whether it represents a successful strategy for high-altitude adaptation. We compared ventilatory, cardiovascular and hematological parameters in: 12 Caucasian yoga trainees and 12 control sea-level residents, at baseline and after 2-week exposure to high altitude (Pyramid Laboratory, Nepal, 5,050 m), 38 active lifestyle high-altitude natives (Sherpas) and 13 contemplative lifestyle high-altitude natives with practice of yoga-like respiratory exercises (Buddhist monks) studied at 5,050 m...
March 2007: European Journal of Applied Physiology
J Viganó, F Abbiati, M Alessiani, M Bonfichi, S Zonta, M Bardone, E Zitelli, L Cobianchi, M Doni, F Lovisetto, T Dominioni, M De Martino, B Lusona, E Arbustini, P Dionigi
As intestinal grafts require heavy immunosuppression, there are no reports of immunosuppression withdrawal after clinical small bowel transplantation. In this large-animal study, we investigated the occurrence of graft rejection in intestinal-transplanted pigs after withdrawal. Large-White unrelated piglets were transplanted and divided in three groups: group 1 (n = 5), intestinal transplantation (ITx) with no immunosuppression; group 2 (n = 7), Itx and 60 days of treatment with tacrolimus and mycophenolate mofetil; group 3 (n = 5), Itx and donor bone marrow infusion (DBMi) and 60 days of treatment with tacrolimus and mycophenolate mofetil...
July 2006: Transplantation Proceedings
Luca Arcaini, Nora Colombo, Paolo Bernasconi, Silvia Calatroni, Francesco Passamonti, Ester Orlandi, Maurizio Bonfichi, Sara Burcheri, Matteo Della Porta, Elisa Rumi, Francesca Montanari, Alessandra Algarotti, Cristiana Pascutto, Mario Lazzarino
Bcl-2/IgH rearrangement is the molecular hallmark of follicular lymphoma which is present in 70 - 90% of cases at diagnosis. The significance of the bcl-2 rearrangement at onset of disease and of its clearing after treatment (molecular response) is still controversial. The aims of the present analysis are: to evaluate the incidence of bcl-2 rearrangement in blood and marrow in a cohort of patients systematically investigated at diagnosis, to describe the correlation between bcl-2 and presenting features, to clarify the correlation of molecular response with outcome...
June 2006: Leukemia & Lymphoma
A Corso, S Mangiacavalli, A Nosari, C Castagnola, P Zappasodi, A M Cafro, C Astori, M Bonfichi, M Varettoni, C Rusconi, D Troletti, C Pascutto, E Morra, M Lazzarino
From 2000 to 2004, 152 patients with multiple myeloma aged <or=65 years, enrolled in high-dose programs, were treated with two schedules of DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin): 106 patients (group I) were mobilized with the infusional version of DCEP (infusional-DCEP), and 46 patients (group II) with a shorter version (DCEP-short). The median number of CD34(+) cells collected was similar in the two groups as was the percentage of patients yielding >or=4 x 10(6) cells/kg. The proportion of patients in whom mobilization failed was similar in the two groups...
December 2005: Bone Marrow Transplantation
Mario Lazzarino, Luca Arcaini, Ester Orlandi, Isabella Iacona, Paolo Bernasconi, Silvia Calatroni, Marzia Varettoni, Luciano Isa, Ercole Brusamolino, Maurizio Bonfichi, Francesco Passamonti, Sara Burcheri, Cristiana Pascutto, Mario Regazzi
PURPOSE: Therapeutic options for relapsed or refractory follicular lymphoma include combination chemotherapy, immunotherapy and, for selected patients, autotransplant. Because of the different mechanisms of action and non-overlapping toxicities, combination of rituximab with chemotherapy is a rational approach. METHODS: 30 patients with follicular non-Hodgkin's lymphoma with advanced-stage disease were treated with four cycles of immunochemotherapy with rituximab 375 mg/m2 on day 1, vincristine 2 mg i...
2005: Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"